Description
A searchable, sortable database of all known CAR-T cell therapy companies worldwide.
For a limited time, you can claim it for an unusual $150 off. Act fast because this offer expires in 48 hours.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”
The CAR-T industry has seen a tremendous number of advancements lately, including a total of 13 global approvals (seven within the U.S., four within China, and two within India), as well as late-stage CAR-T products advancing through the clinical pipeline. There have also been incredible M&A activity, including most recently, Gilead Sciences acquiring Arcellx in a transaction valued at an astounding $7.8 billion, highlighting the high strategic and financial stakes in this sector. This move positioned Gilead to have full ownership of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy, if it reaches commercialization. Aanito‑cel is currently in Phase 2 and Phase 3 trials for relapsed or refractory multiple myeloma and Phase 1 trials for autoimmune diseases.
Progress with in vivo CAR-T technologies has also been accelerating at a profound rate in recent months, with AstraZeneca, AbbVie, Gilead Sciences, and Bristol Myers Squibb all making significant acquisitions to accelerate their capabilities with in vivo CAR-T and RNA-based delivery technologies. In vivo CAR-T cell therapies, which engineer immune cells directly within the patient rather than through external manufacturing, have the potential to dramatically reduce costs, shorten production timelines, and broaden patient access to these transformative treatments.
To track the competitors in this fast-growing space, BioInformant has compiled a global database of all known CAR-T cell therapy companies, currently 259 worldwide.
Originally developed for internal use, this resource is now available to readers who want an immediate and authoritative view of the market.
CAR-T Industry Database
Between 2017 and today, at least 13 CAR-T products have reached commercialization. Of these, seven are U.S. FDA-approved CAR-T cell therapies, each of which have received approvals in other major healthcare markets as well. The seven U.S. FDA approved products include:
- Kymriah (tisagenlecleucel)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Breyanzi (lisocabtagene maraleucel)
- Abecma (idecabtagene vicleucel)
- Carvykti (Ciltacabtagene autoleucel)
- Aucatzyl (obecabtagene autoleucel)
In addition to the CAR-T cell therapies listed above, four CAR-T therapies have received approval from the Chinese National Medical Products Administration (NMPA) and two have received approval from the Indian Central Drugs Standard Control Organisation (CDSCO).
These historic approvals have driven the CAR-T market to staggering new heights and fueled interest into CAR-T cell therapy development.
This database features the following information for all known CAR-T market competitors:
-
Company Name
-
CAR-T Technology
-
CAR-T Disease Targets
-
Description of CAR-T Involvement
-
Country of Operations (Headquarters)
-
City / State
-
Link to CAR-T Programs
-
Company Website
Proprietary Insights
It takes our analysts hundreds of hours of diligent work to uncover these CAR-T market competitors from across the globe. Importantly, we utilize translators and crowd-source ongoing feedback from BioInformant’s partners, clients, colleagues, and global readership.
Thus, this database includes little known competitors and companies emerging from stealth mode that would be difficult to identify if you had not been tracking this industry daily for the past 19+ years (as BioInformant has done since 2006).
Best of all, you don’t have to worry about AI errors or inaccuracies, which are common in rapidly evolving nature of this industry. If you want immediate and actionable insights from a trusted, U.S. based provider that specializes exclusively in the cell therapy market, then this database is for you.
You can claim it to:
- Identify global competitors across the CAR-T marketplace
- Reveal preclinical and clinical programs supporting CAR-T development
- Spot regions that are “hotspots” for CAR-T companies
- Identify potential partners and collaborators
- Become immediately informed, without the need for research, time, or effort
Would you benefit from knowing all known CAR-T market competitors worldwide, including their technologies under development, disease targets, and CAR-T involvement?
If so, you can access the information instantly and effortlessly below.
Guarantee
When you check out below, your product will be delivered immediately as an Excel download. Of course, your investment is backed by a 100% Money Back Guarantee.
To view License Descriptions, please click here.
![[NEW] Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2026](https://bioinformant.com/wp-content/uploads/2016/03/iPS-Cell-Report-400x400.png)
